Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma1
Open Access
- 1 January 2006
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 8 (1), 67-78
- https://doi.org/10.1215/s1522851705000451
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- TRIBUTE: A Phase III Trial of Erlotinib Hydrochloride (OSI-774) Combined With Carboplatin and Paclitaxel Chemotherapy in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Erlotinib in Previously Treated Non–Small-Cell Lung CancerNew England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft modelsAnti-Cancer Drugs, 2004
- Resistance to Tyrosine Kinase Inhibition by Mutant Epidermal Growth Factor Receptor Variant III Contributes to the Neoplastic Phenotype of Glioblastoma MultiformeClinical Cancer Research, 2004
- Phase II Trial of Gefitinib in Recurrent GlioblastomaJournal of Clinical Oncology, 2004
- 33 Phase I study of OSI-774 alone or with temozolomide in patients with malignant gliomaEuropean Journal of Cancer Supplements, 2003
- Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trialsThe Lancet, 2002
- Epidermal growth factor-related peptides and their receptors in human malignanciesCritical Reviews in Oncology/Hematology, 1995
- A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity.Proceedings of the National Academy of Sciences, 1994